Insight into Pharmaceutical Ingredients
With CPhI just around the corner, we've made pharmaceutical ingredients the focus of the September issue of PTE Digital. In particular, experts examine the challenges of highly potent ingredients. In addition, this month's issue covers paediatric medicines, the problems of tablet sticking and cargo security. More... |
 |
|
| |
Regulatory Intervention in Paediatric Medicines
Regulators have attempted to stimulate paediatric-drug development with incentives offering extended periods of patent protection, but are these actions having the desired effects? Nathan Jessop examines the concerns of some in the industry who believe these incentives may be being misused. More... |
 |
|
| |
Strategies for High Containment
In this roundtable, experts share insight on facility design and operations for high-potency manufacturing, including the main considerations in equipment and facility selection, as well as how to effectively monitor and control risk. More... |
 |
|
| |
Pharmaceutical-Based Cargo Security and Theft Prevention
A rise in the incidence of cargo thefts in the pharmaceutical industry requires a cross-functional response from individual companies, the industry, law-enforcement organisations and other stakeholders. The author discusses strategies for a proactive cargo security and antitheft program, including best practices used by Pfizer. More... |
 |
|
| |
News Bites and Twitter Trends
If you’ve missed out on some of the top news stories about the pharmaceutical industry recently then our news roundup will update you. Highlights include GSK divestures and the UK’s high-tech stem cell centre. We also bring you a summary of some of the latest headlines from Twitter. More... |
 |
|
|
 |
|
 |
| |
 |
| |
|
| Has your company started implementing procedures and practices required by Europe's new pharmacovigilance legislation? |
|
Yes |
85% |
| |
|
No |
5% |
| |
|
|
|
We are making progress |
10% |
This week we would like to know...
What do you think will be the greatest benefit of FDA's Generic Drug User Fees Amendments of 2012 (GDUFA)?
|
|
Contact Us
Click here to contact editorial.
Click here to contact sales. |
|
